- By collecting segmented medical data and analyzing it with AI, we support providing more personalized medical care tailored to each patient's needs.
- We plan to provide genetic testing, collection and analysis of medical data, and treatment proposals using AI.
- Through collaboration with core hospitals responsible for cancer genome medical care and construction of networks beyond hospital barriers.
SoftBank Group Corp. (SBG) announces the establishment of a joint venture company with Tempus AI, Inc. (Tempus), a leading company in AI and precision medicine, called SB TEMPUS Co., Ltd. The joint venture agreement was signed in May 2024, and is expected to be completed in July 2024 after meeting general closing requirements. SBG and Tempus will each invest 15 billion yen upon the completion of closing. SB TEMPUS was established to provide personalized medical services utilizing the knowledge and technology accumulated by Tempus in the United States, aiming to further advance Japan's healthcare through the use of AI.
Tempus, established in 2015, promotes personalized medicine using AI in the healthcare field. Tempus collaborates with approximately 50% of oncologists in the United States and owns the industry's largest anonymized library of molecular, clinical, and imaging data. Tempus' AI-enabled platform supports more intelligent diagnoses, data-driven decision making by healthcare providers, and more effective development of treatments by pharmaceutical companies. Tempus' shares have been listed on the NASDAQ Global Select Market since June 14, 2024.
Cancer treatment in Japan today is based on evidence-based 'standard treatment' such as surgical treatment, radiotherapy, and drug therapy. Collecting and analyzing data currently fragmented in the medical field, such as molecular, clinical, pathological, and medical image data, not only contributes to the advancement of medical and drug research, but also leads to the proposes of better individualized treatment options, reducing side effects, and improving drug efficacy, taking a big step towards personalized medicine.
SB TEMPUS plans to sequentially provide individualized medical care, such as genetic testing, collection and analysis of medical data, and AI-based treatment proposals, without accessing patient identification data using the knowledge and technology accumulated through Tempus' operations in the United States. To help as many people suffering from cancer as possible, we will support the provision of better diagnosis and treatment by building cooperative relationships not only with core hospitals responsible for cancer genome medical care, but also with hospitals and medical facilities, pharmaceutical companies, biotechnology ventures, medical device companies, cancer insurance companies, and inspection companies in Japan.
SoftBank Group has the management philosophy of 'Happily Revolutionizing Information.' With Tempus, a leading company in personalized medicine using AI, we will contribute to the radical advancement of medical care by promoting diagnosis and treatment based on medical data and AI, while closely collaborating with Japan's medical industry.
Masayoshi Son, Representative Director, Chairman & CEO of SoftBank Group, said: 'I am very pleased to be able to deploy a joint venture with Tempus, which contributes to the progress of medicine in Japan. By promoting high-quality personalized medicine using AI, I strongly hope to reduce people's sadness even a little bit and increase the happiness of as many people as possible.'
Eric Lefkofsky, founder and CEO of Tempus, said: 'At Tempus, we are working to transform personalized medicine through practical AI applications. Through partnership with SBG, we will be able to provide healthcare solutions using AI in Japan. Together with SBG, we aim to support patients to receive personalized, data-driven treatment and to lead longer and healthier lives.'
Company overview of SB Tempus.
| Company name | SB Tempus Corporation (English name: SB Tempus Corp.) |
|---|---|
| Representative | Hidefumi Kitahara |
| Director | Takeishi Tsutsui, Kazuhisa Shibayama, Ryan Fukushima, Andy Polovin, Jim Rogers |
| Location | 1-7-1 Kaigan, Minato-ku, Tokyo Port City Takeshiba Office Tower |
| Capital | 30 billion yen |
| Business Description | Genetic testing, medical data collection and analysis, and AI-based treatment recommendations (planned) |
| Investment ratio | SoftBank Group Corp 50%, Tempus AI Inc. 50% (joint controlling company) |
| URL | https://www.sbtempus.com |
About Tempus
Tempus is a technology company driving personalized medicine through AI-based practical applications in healthcare. Using the world's largest multi-modal data library and an operating system that makes data accessible and useful, Tempus offers precision medicine solutions for physicians using AI, enabling individualized treatment depending on each patient's condition, and supports discovering, developing, and providing optimal treatment. In addition, Tempus provides physicians with tools that learn from collecting more data so that each individual patient can benefit from past patient treatment results. For more information,https://www.tempus.com
Please see it.
Presentation materials from the press conference held on June 27, 2024 can be viewed at here